Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study.

Jusheng An Jie Tang Benjamin X Li Huihua Xiong Hui Qiu Lin Luo Li Wang Danbo Wang Qi Zhou Qin Xu Honglin Song Yunyan Zhang Hongping Zhang Yujie Li Xiaohui Yu Jing Zhang Rachel Ng Wayne Zhao Michael Wong Xiangrong Dai Guiling Li Ling-Ying Wu

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our study demonstrates that socazolimab has durable safety and efficacy for the treatment of recurrent or metastatic cervical cancer and exhibits a safety profile similar to other anti-PD-1/PD-L1 mAbs.

Keyphrases

squamous cell carcinoma
small cell lung cancer
clinical trial
open label
study protocol
replacement therapy